Crescent Biopharma CBIO
NASDAQ CBIO
$13.17 +0.10 (+0.77%)
At close: Oct 21, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) Receivables (2015 - 2025)

Updated

Crescent Biopharma's Receivables was $18 million in Q4 2025, compared with $136,580 a year earlier.

Analysis

Crescent Biopharma (CBIO) Receivables (2015 - 2025) Analysis & Trends

  • In earlier years, Receivables was $136,580 in FY2024.
  • The Q4 2025 figure marks the highest quarterly Receivables since Q2 2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 19.05 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 13.82 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 15.68 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 12.49 Bn
10 Crescent Biopharma 401.19 Mn -306.10 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 18.00 Mn
Dec 31, 2024 136,580.00
Jun 30, 2015 20.00 Mn
API Access

Crescent Biopharma Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=CBIO&period=max&api_key=YOUR_API_KEY